Drug firm Cipla on Saturday said it has acquired four brands from Wanbury Ltd to strengthen its presence in the women’s health segment.

While Cipla did not provide any financial details of the acquisition, according to a regulatory filing by Wanbury, it has received up to Rs 88.60 crore for the sale of the brands to Cipla.

Cipla has acquired the four brands — CPink, CDense, Productiv and Folinine — to strengthen its presence in the women’s health segment, Cipla said in a filing to the BSE.

The nutraceutical products, to be sold under the four umbrella brands, would address various health needs for conditions arising because of nutritional deficiencies or insufficiencies, it added.

This includes supplements such as multivitamins, multi-mineral and anti-oxidants for adolescent girls, pregnant and lactating women, women going through menopause and for male and female reproductive health, Cipla said.

“We are focused on strengthening our women’s health segment by amplifying our four-decade long presence in this category. Through this newly acquired portfolio, we shall be catering to a wide range of patient needs, including nutritional deficiencies, bone health and sexual health,” said Nikhil Chopra, India business head of Cipla.